PDSB Jumps As JAMA Data And Nant Capital Deal Shift Outlook

PDS Biotechnology Corporation stocks have been trading up by 12.5 percent following promising immunotherapy trial results boosting investor optimism.

Live Update At 12:32:15 EDT: On Tuesday, October 13, 2026 PDS Biotechnology Corporation stock [NASDAQ: PDSB] is trending up by 12.5%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

PDSB has been trading like a classic small-cap biotech rollercoaster. In late September, PDSB sat under $0.80. By 2026/10/13, the stock closed at $1.71 after hitting $1.79 intraday. That’s more than a double in a couple of weeks, driven by news and momentum rather than profits.

Intraday, PDSB shows strong range expansion. Today’s 5-minute chart reveals a steady grind from the mid-$1.40s premarket to highs near $1.79 late morning, then consolidation above $1.70. For short-term traders, that’s a textbook trend day with dips getting bought.

Fundamentally, PDS Biotechnology is still deep in the red. Quarterly net loss is about $9.8M, with operating cash flow around -$2.8M and free cash flow also negative. Cash on the balance sheet is roughly $5.6M, backed by an enterprise value near $98.8M. Current ratio at 0.6 and quick ratio at 0.5 flag a tight liquidity setup, which explains why PDSB turned to a low-priced PIPE.

Returns on equity and assets are sharply negative, which is normal for a clinical-stage biotech but a reminder that PDSB is a story stock. For traders, the thesis revolves around data and deals, not current earnings power.

Why Traders Are Watching PDSB Now

PDSB is back on the radar because the science finally has peer-reviewed backing and the money side just got reshuffled. The big catalyst is the Phase 2 VERSATILE-002 data in JAMA Oncology. PDS Biotechnology reported that PDS0101 plus pembrolizumab hit a 36% objective response rate in CPS ≥1 HPV16-positive recurrent or metastatic head and neck cancer. Historically, pembrolizumab alone runs closer to 19%. Median overall survival of 39.3 months and a safety profile in line with standard of care make this more than a headline — it’s real clinical validation.

For PDSB, that de-risks PDS0101 and gives the company something concrete to walk into partnership talks with. At the same time, management is clearly shifting internal firepower toward PDS0301, its IL-12 immunocytokine, in metastatic colorectal cancer. The plan is to prioritize PDS0301 in-house and look to partner or even out-license PDS0101.

That’s where Nant Capital and NantWorks step in. The recent PIPE brought in about $11.3M at roughly $0.28 per unit, with the deal sized up to $22.3M if a Phase 3 protocol for PDS0301 gets submitted. The pricing is ugly for existing PDSB holders, which is why the stock dropped more than 8% on the deal news. But the cash extends the runway and ties future financing to clinical milestones.

NantWorks also secured a one-year exclusive option to negotiate a PDS0101 license, and PDS Biotechnology added Patrick Soon-Shiong and NantBio CFO James Banaag to its board. That kind of strategic alignment often signals deeper involvement and potential follow-on capital. Layer on a new Schedule 13D disclosing a sizable PDSB stake by an active holder, and traders suddenly have multiple potential catalysts: data, deals, and governance moves.

Conclusion

PDSB is walking a tightrope that every micro-cap biotech knows well: strong science on one side, brutal financing reality on the other. PDS Biotechnology just printed peer-reviewed Phase 2 data showing PDS0101 plus pembrolizumab beating historical benchmarks on both response and survival in a tough HPV16-positive head and neck cancer setting. That is not noise; it is the kind of dataset that supports partnering talks and adds long-term optionality.

At the same time, the balance sheet forced PDSB into a highly dilutive PIPE at around $0.28 with warrants layered on. That deal knocked the stock over 8% and tells traders exactly how the market was valuing the risk before the latest surge. The cash, though, is earmarked to push PDS0301 in metastatic colorectal cancer toward a Phase 3-enabling path, which is where the next big binary event lives.

Add in NantWorks’ exclusive negotiation window on a PDS0101 license, the arrival of Patrick Soon-Shiong and James Banaag on the PDS Biotechnology board, and a new Schedule 13D holder, and you have a crowded catalyst calendar. For active traders, PDSB is now a pure sentiment-and-headlines setup.

As Tim Sykes loves to say, “Patterns repeat because human nature doesn’t change.” As millionaire penny stock trader and teacher Tim Sykes, says, “There is always another play around the corner; don’t chase just because you feel FOMO.”. With PDSB ripping off sub-$1 lows into a news storm, the key is the same as always — study the chart, respect the dilution risk, and cut losses fast if the pattern breaks. This article is for educational and research purposes only and is not investment advice.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

• Penny Stocks Trading Guide
• Best Penny Stocks Under $1 to Buy Today
• Top 8 Penny Stocks to Watch on Robinhood

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks